Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 3/2014

01.09.2014 | Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-Prevention

verfasst von: M.-J. Milloy, Julio S. G. Montaner, Evan Wood

Erschienen in: Current HIV/AIDS Reports | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Contact with the criminal justice system, including incarceration, is a common experience for many people living with HIV/AIDS. Optimism has recently been expressed that correctional facilities could be important locations for treatment-as-prevention (TasP)-based initiatives. We review recent findings regarding the effect of incarceration on patterns of HIV transmission, testing, treatment initiation and retention. We found that the prevalence of HIV infection among incarcerated individuals remains higher than analogous non-incarcerated populations. Recent studies have shown that voluntary HIV/AIDS testing is feasible in many correctional facilities, although the number of previously undiagnosed individuals identified has been modest. Studies have implied enhanced linkage to HIV/AIDS treatment and care in jails in the United States was associated with improvements in the HIV cascade of care. However, for many individuals living with HIV/AIDS, exposure to the correctional system remains an important barrier to retention in HIV/AIDS treatment and care. Future research should evaluate structural interventions to address these barriers and facilitate the scale-up of TasP-based efforts among individuals living in correctional settings.
Literatur
1.
Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94:1218–23.PubMedCentralPubMedCrossRef
2.
Rotily M, Weilandt C, Bird SM, Käll K, Van Haastrecht HJ, Iandolo E, et al. Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. Eur J Pub Health. 2001;11:243–50.CrossRef
3.
Allwright S. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ. 2000;321:78–82.PubMedCentralPubMedCrossRef
4.
Amiya RM, Cope JE, Poudel KC, Jimba M. At the intersection of public health and criminal justice systems. Lancet. 2013;381:534.PubMedCrossRef
5.
Centers for Disease Control and Prevention (CDC). HIV transmission among male inmates in a state prison system--Georgia, 1992-2005. MMWR Morb Mortal Wkly Rep. 2006;55:421–6.
6.
Dolan KA, Wodak A. HIV transmission in a prison system in an Australian State. Med J Aust. 1999;171:14–7.PubMed
7.
8.
Zack B. Correctional health and the HIV stages of care. J Correct Health Care. 2013;19:229–30.PubMedCrossRef
9.•
Jürgens R, Nowak M, Day M. HIV and incarceration: prisons and detention. J Int AIDS Soc. 2011;14:26. The most comprehensive review of the epidemiological, clinical and policy implications of incarceration among individuals living with/at risk of HIV.PubMedCentralPubMedCrossRef
10.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367–87.PubMedCrossRef
11.
Walmsley R. World prison population list. 9th ed. Essex: International Centre for Prison Studies; 2013. p. 1–6.
12.
Incarceration and crime: a complex relationship. Washington, DC: The Sentencing Project; 2005; pp. 1–11.
13.
Blumstein A, Beck AJ. Population growth in US prisons, 1980-1996. Crime Just. 1999;26:17.CrossRef
14.
West H, Sabol WJ, Greenman S. Prisoners in 2009. Washington, DC: United States Department of Justice; 2011. p. 1–38.
15.•
Rich JD, Diclemente R, Levy J, Lyda K, Ruiz MS, Rosen DL, et al. Correctional facilities as partners in reducing HIV disparities. J Acquir Immune Defic Syndr. 2013;63 Suppl 1:S49–53. An important call from leading US-based researchers into correctional health to engage correctional facilities in addressing HIV/AIDS-associated disparities.PubMedCentralPubMedCrossRef
16.
Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA J Am Med Assoc. 2009;301:183–90.CrossRef
17.•
Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013;26:10–6. A review of seek, test, treat and retain campaigns among incarcerated individuals in the United States.PubMedCentralPubMedCrossRef
18.
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4:A16–21.
19.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCentralPubMedCrossRef
20.
Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–9.PubMedCentralPubMedCrossRef
21.
Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE. 2012;7:e30216.PubMedCentralPubMedCrossRef
22.
Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531–6.PubMedCrossRef
23.
Draine J, Ahuja D, Altice FL, Arriola KJ, Avery AK, Beckwith CG, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. Aids Care Psychol Socio-Med Asp Aids-Hiv. 2011;23:366–77.
24.
Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53:725–31.PubMedCentralPubMedCrossRef
25.
Milloy M-J, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS. 2012;26:60–7.PubMedCentralPubMedCrossRef
26.
Clatts MC, Rodriguez-Diaz CE, Garcia H, Vargas-Molina RL, Jovet-Toledo GG, Goldsamt LA. Preliminary evidence of significant gaps in continuity of HIV care among excarcerated populations in Puerto Rico. J Int Assoc Physicians AIDS Care (JIAPAC). 2011;10:339–41.CrossRef
27.
Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for ‘treatment as prevention”. Curr Opin HIV AIDS. 2012;7:332–8.PubMedCrossRef
28.
Rich JD, Dickinson BP, Macalino G, Flanigan TP, Towe CW, Spaulding A, et al. Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. JAIDS J Acquir Immune Defic Syndr. 1999;22:161–6.
29.
Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H. Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000;34:431–6.PubMedCrossRef
30.
Tyndall MW, Currie S, Spittal P, Li K, Wood E, O’shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17:887–93.PubMedCrossRef
31.
Choopanya K, Jarlais Des DC, Vanichseni S, Kitayaporn D, Mock PA, Raktham S, et al. Incarceration and risk for HIV infection among injection drug users in Bangkok. JAIDS J Acquir Immune Defic Syndr. 2002;29:86–94.
32.
Reekie JM, Levy MH, Richards AH, Wake CJ, Siddall DA, Beasley HM, et al. Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010. Med J Aust. 2014;200:277–80.PubMedCrossRef
33.•
Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS ONE. 2013;8:e59643. The authors present the results from a representative survey of HIV and related matters among recently-released Ukranian prisoners.PubMedCentralPubMedCrossRef
34.••
Henostroza G, Topp SM, Hatwiinda S, Maggard KR, Phiri W, Harris JB, et al. The high burden of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public health alert. PLoS ONE. 2013;8:e67338. In the first published survey of its kind, the authors present the results of a screening programme for HIV and TB in a large Zambian prison, establishing that correctional-associated HIV transmission and pathogenesis should be an urgent priority in efforts to address the pandemic in Sub-Saharan Africa.PubMedCentralPubMedCrossRef
35.
Mohamed HI, Saad ZM, Abd-Elreheem EM, Abd-ElGhany WM, Mohamed MS, Abd Elnaeem EA, et al. Hepatitis C, hepatitis B and HIV infection among Egyptian prisoners: seroprevalence, risk factors and related chronic liver diseases. J Infect Public Health. 2013;6:186–95.PubMedCrossRef
36.
Semaille C, Le Strat Y, Chiron E, Chemlal K, Valantin MA, Serre P, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18.
37.
Honarvar B, Odoomi N, Moghadami M, Afsar Kazerooni P, Hassanabadi A, Zare Dolatabadi P, et al. Blood-borne hepatitis in opiate users in Iran: a poor outlook and urgent need to change nationwide screening policy. PLoS ONE. 2013;8:e82230.PubMedCentralPubMedCrossRef
38.
Vagenas P, Azbel L, Polonsky M, Kerimi N, Mamyrov M, Dvoryak S, et al. A review of medical and substance use co-morbidities in Central Asian prisons: implications for HIV prevention and treatment. Drug Alcohol Depend. 2013;132 Suppl 1:S25–31.PubMedCrossRef
39.
Telisinghe L, Fielding KL, Malden JL, Hanifa Y, Churchyard GJ, Grant AD, et al. High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. PLoS ONE. 2014;9:e87262.PubMedCentralPubMedCrossRef
40.
Winetsky DE, Almukhamedov O, Pulatov D, Vezhnina N, Dooronbekova A, Zhussupov B. Prevalence, risk factors and social context of active pulmonary tuberculosis among prison inmates in Tajikistan. PLoS ONE. 2014;9:e86046.PubMedCentralPubMedCrossRef
41.
Margolis B, Al-Darraji HAA, Wickersham JA, Kamarulzaman A, Altice FL. Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. Int J Tuberc Lung Dis. 2013;17:1538–44.PubMedCentralPubMedCrossRef
42.
Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91:36–45.PubMedCentralPubMedCrossRef
43.
Milloy M-J, Wood E, Tyndall M, Lai C, Montaner J, Kerr T. Recent incarceration and use of a supervised injection facility in Vancouver, Canada. Addict Res Theory. 2009;17:538–45.CrossRef
44.
Buavirat A. Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ. 2003;326:308.PubMedCentralPubMedCrossRef
45.
Epperson M, El-Bassel N, Gilbert L, Orellana ER, Chang M. Increased HIV risk associated with criminal justice involvement among men on methadone. AIDS Behav. 2007;12:51–7.PubMedCentralPubMedCrossRef
46.
Widman L, Noar SM, Golin CE, Willoughby JF, Crosby R. Incarceration and unstable housing interact to predict sexual risk behaviours among African American STD clinic patients. Int J STD AIDS. 2014;25:348–54.PubMedCrossRef
47.
Brewer RA, Magnus M, Kuo I, Wang L, Liu T-Y, Mayer KH. Exploring the relationship between incarceration and HIV among black men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2014;65:218–25.PubMedCrossRef
48.•
Brewer RA, Magnus M, Kuo I, Wang L, Liu T-Y, Mayer KH. The high prevalence of incarceration history among Black men who have sex with men in the United States: associations and implications. Am J Public Health. 2014;104:448–54. An important analysis of the effects of mass incarceration on Black men who have sex with men in the United States.PubMedCrossRef
49.
Alexander M. The new Jim Crow. The New Press; 2013.
50.
Millett GA, Peterson JL, Wolitski RJ, Stall R. Greater risk for HIV infection of black men who have sex with men: a critical literature review. Am J Public Health. 2006;96:1007–19.PubMedCentralPubMedCrossRef
51.
Halkitis PN, Kapadia F, Siconolfi DE, Moeller RW, Figueroa RP, Barton SC, et al. Individual, psychosocial, and social correlates of unprotected anal intercourse in a new generation of young men who have sex with men in New York City. Am J Public Health. 2013;103:889–95.PubMedCentralPubMedCrossRef
52.
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 2006;1–17.
53.
Branson BM, Viall A, Marum E. Expanding HIV testing: back to the future. JAIDS J Acquir Immune Defic Syndr. 2013;63:S117.
54.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.PubMedCrossRef
55.
Yang Q, Boulos D, Yan P, Zhang F, Remis RS, Schanzer D, et al. Estimates of the number of prevalent and incident human immunodeficiency virus (HIV) infections in Canada, 2008. Can J Public Health. 2010;101:486–90.PubMed
56.
Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA J Am Med Assoc. 2009;301:2380–2.CrossRef
57.•
Gagnon M, Jacob JD, Cormier L. Total control: a critical analysis of mandatory HIV testing in U.S. prisons. J Forensic Nurs. 2013;9:154–61. The authors summarize the substantial ethical, legal and human rights concerns around HIV testing in US correctional settings.PubMedCrossRef
58.
Seal DW, Eldridge GD, Zack B, Sosman J. HIV testing and treatment with correctional populations: people, not prisoners. J Health Care Poor Underserved. 2010;21:977–85.PubMedCentralPubMedCrossRef
59.
HIV testing and counselling in prisons and other closed settings. Geneva: United Nations Office on Drug Control and Crime; 2009 pp. 1–72.
60.
Pope JL. HIV testing in state correctional systems. JL Health. 2009;22:17.
61.
HIV/AIDS prevention, care, treatment and support in prison settings. New York City: United Nations Office on Drugs and Crime; 2006, pp. 1–50.
62.
Spaulding AC, Booker CA, Freeman SH, Ball SW, Stein MS, Jordan AO, et al. Jails, HIV testing, and linkage to care services: an overview of the EnhanceLink initiative. AIDS Behav. 2013;17 Suppl 2:S100–7.PubMedCrossRef
63.
de Voux A, Spaulding AC, Beckwith C, Avery A, Williams C, Messina LC, et al. Early identification of HIV: empirical support for jail-based screening. PLoS ONE. 2012;7.
64.
Beckwith CG, Nunn A, Baucom S, Getachew A, Akinwumi A, Herdman B, et al. Rapid HIV testing in large urban jails. Am J Public Health. 2012;102 Suppl 2:S184–6.PubMedCentralPubMedCrossRef
65.
Centers for Disease Control and Prevention (CDC). Routine HIV screening during intake medical evaluation at a County Jail - Fulton County, Georgia, 2011-2012. MMWR Morb Mortal Wkly Rep. 2013;62:495–7.
66.•
Solomon L, Montague BT, Beckwith CG, Baillargeon J, Costa M, Dumont D, et al. Survey finds that many prisons and jails have room to improve HIV testing and coordination of postrelease treatment. Health Aff (Millwood). 2014;33:434–42. This survey of prison and jail systems in the United States reveals that a low proportion of settings offer HIV testing and linkage consistent with official guidelines.CrossRef
67.
Wohl DA, Golin C, Rosen DL, May JM, White BL. Detection of undiagnosed HIV among state prison entrants. JAMA J Am Med Assoc. 2013;310:2198–9.CrossRef
68.
Springer S, Friedland G, Doros G, Pesanti E, Altice F. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials. 2007;8:205–12.PubMedCentralPubMedCrossRef
69.
Babudieri S, Aceti A, D’Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA J Am Med Assoc. 2000;284:179–80.CrossRef
70.•
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014. doi:10.​1001/​jamainternmed.​2014.​601. This retrospective review of all known individuals living with HIV/AIDS in a US state correctional system found substantial improvements in virologic control during incarceration.PubMedCentral
71.•
Davies N, Karstaedt AS. Antiretroviral outcomes in South African prisoners: a retrospective cohort analysis. PLoS ONE. 2012;7. This small study of individuals in the South African prison system reported virologic outcomes comparable to that observed in high-resource settings.
72.
Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, et al. Accessing antiretroviral therapy following release from prison. JAMA J Am Med Assoc. 2009;301:848–57.CrossRef
73.
74.
Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356:157–65.PubMedCentralPubMedCrossRef
75.•
Booker CA, Flygare CT, Solomon L, Ball SW, Pustell MR, Bazerman LB, et al. Linkage to HIV care for jail detainees: findings from detention to the first 30 days after release. AIDS Behav. 2013;17 Suppl 2:S128–36. This study identified important correlates of successful linkage following incarceration, including stable housing, in individuals participating in the EnhanceLink initiative.PubMedCrossRef
76.
Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21:708–14.PubMedCrossRef
77.
Milloy M-J, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203:1215–21.PubMedCentralPubMedCrossRef
78.
Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17:539–49.PubMedCrossRef
79.
Milloy M-J, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S, et al. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;59:393–9.PubMedCentralPubMedCrossRef
80.•
Youmans E, Burch J, Moran R, Smith L, Duffus WA. Disease progression and characteristics of HIV-infected women with and without a history of criminal justice involvement. AIDS Behav. 2013;17:2644–53. This study describes how women with a history of involvement in the criminal justice system exhibit faster disease progression.PubMedCrossRef
81.
Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27:2559–66.PubMedCentralPubMedCrossRef
82.
Pecoraro A, Royer-Malvestuto C, Rosenwasser B, Moore K, Howell A, Ma M, et al. Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States. AIDS Care. 2013;25:1399–406.PubMedCrossRef
83.
Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013;133:154–60.PubMedCrossRef
84.
Springer SA, Qiu JJ, Saber-Tehrani AS, Altice FL. retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS ONE. 2012;7.
85.•
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend. 2013;132:378–82. This study reveals how methadone dose at time of release from prison improved retention in treatment among formerly-incarcerated prisoners in Malaysia.PubMedCrossRef
86.
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014;37:209–18.PubMedCrossRef
87.
Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. Am J Public Health. 2014;104:434–41.PubMedCentralPubMedCrossRef
88.
Althoff AL, Zelenev A, Meyer JP, Fu J, Brown S-E, Vagenas P, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2013;17 Suppl 2:S156–70.PubMedCrossRef
89.
Avery AK, Ciomcia RW, Lincoln T, Desbrais M, Jordan AO, Rana AI, et al. Jails as an opportunity to increase engagement in HIV care: findings from an observational cross-sectional study. AIDS Behav. 2013;17 Suppl 2:S137–44.PubMedCrossRef
90.
Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, et al. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav. 2013;17:2654–66.PubMedCrossRef
91.
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, et al. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav. 2013;17 Suppl 2:S118–27.PubMedCrossRef
92.
Jordan AO, Cohen LR, Harriman G, Teixeira PA, Cruzado-Quiñones J, Venters H. Transitional care coordination in New York City jails: facilitating linkages to care for people with HIV returning home from Rikers Island. AIDS Behav. 2013;17 Suppl 2:S212–9.PubMedCrossRef
93.
Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, et al. Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS Behav. 2013;17 Suppl 2:S171–80.PubMedCrossRef
94.
Spaulding AC, Pinkerton SD, Superak H, Cunningham MJ, Resch S, Jordan AO, et al. Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention. AIDS Behav. 2013;17 Suppl 2:S220–6.PubMedCrossRef
95.
Williams CT, Kim S, Meyer J, Spaulding A, Teixeira P, Avery A, et al. Gender differences in baseline health, needs at release, and predictors of care engagement among HIV-positive clients leaving jail. AIDS Behav. 2013;17 Suppl 2:S195–202.PubMedCrossRef
96.
Zelenev A, Marcus R, Kopelev A, Cruzado-Quiñones J, Spaulding A, Desabrais M, et al. Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav. 2013;17 Suppl 2:S181–94.PubMedCrossRef
97.
Spaulding AC, Messina LC, Kim BI, Chung K-W, Lincoln T, Teixeira P, et al. Planning for success predicts virus suppressed: results of a non-controlled, observational study of factors associated with viral suppression among HIV-positive persons following jail release. AIDS Behav. 2013;17 Suppl 2:S203–11.PubMedCrossRef
98.
Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.PubMedCentralPubMedCrossRef
99.
Milloy M-J, Kerr T, Salters K, Samji H, Guillemi S, Montaner J, et al. Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis. BMC Infect Dis. 2013;13:565.PubMedCentralPubMedCrossRef
100.
Prellwitz IM, Alves BM, Ikeda MLR, Kuhleis D, Picon PD, Jarczewski CA, et al. HIV behind bars: human immunodeficiency virus cluster analysis and drug resistance in a reference correctional unit from southern Brazil. PLoS ONE. 2013;8:e69033.PubMedCentralPubMedCrossRef
101.
Menezes P, Rosen D, Wohl DA, Kiziah N, Sebastian J, Eron JJJ, et al. Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States. AIDS Res Hum Retrovir. 2013;29:136–41.PubMedCentralPubMedCrossRef
102.
Montaner JSG, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS ONE. 2014;9:e87872.PubMedCentralPubMedCrossRef
103.
Cescon A, Kanters S, Brumme CJ, Lepik KJ, Forrest JI, Hull M, et al. Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010. J. Acquir Immune Defic Syndr. 2013.
104.
Jürgens R, Betteridge G. Prisoners who inject drugs: public health and human rights imperatives. Health Hum Rights. 2005;8:46–74.PubMedCrossRef
Metadaten
Titel
Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-Prevention
verfasst von
M.-J. Milloy
Julio S. G. Montaner
Evan Wood
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 3/2014
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-014-0214-z

Weitere Artikel der Ausgabe 3/2014

Current HIV/AIDS Reports 3/2014 Zur Ausgabe

Complications of Antiretroviral Therapy (JM Kilby, Section Editor)

Differentiating HIV-associated Nephropathy from Antiretroviral Drug-Induced Nephropathy: A Clinical Challenge

Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

Vitamin D Deficiency and Altered Bone Mineral Metabolism in HIV-infected Individuals

Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

Depression and Adherence to Antiretroviral Therapy in Low-, Middle- and High-Income Countries: A Systematic Review and Meta-Analysis

Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

HPV and Anal Cancer in HIV-Infected Individuals: A Review

Central Nervous System and Cognition (I Grant, Section Editor)

Host Genetic Factors Predisposing to HIV-Associated Neurocognitive Disorder

Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise